Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients

Antonio Drago, Barbara Monti, Diana De Ronchi, Alessandro Serretti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The genetic background of the antidepressant response to pharmacological treatment in bipolar disorder (BD) remains elusive. This issue is of primary relevance in that the depressive phases of BD are difficult to treat and they are associated with suicide. Aim: We investigated the role of a set of genetic variations (single-nucleotide polymorphisms) harbored by matrix metalloproteinases (MMPs) as predictors of response to treatment in depressed BD patients. Methods: 654 BD patients from the publicly available Systematic Treatment Enhancement Program for Bipolar Disorder study were investigated. The outcome was the number of depressive events corrected by the number of times patients were assessed. Clinical and sociodemographic variables were tested as possible stratification factors and included in the analysis if necessary. Genetic predictors were 43 SNPs harbored by 17 MMPs. Imputation, quality check and pruning were conducted according to standards. Results were corrected for multitesting. Results: rs486055 (MMP-10) was associated with the outcome. TT homozygotes had 5.08 ± 3.51 events, CT had 3.47 ± 3.18 and CC had 2.57 ± 2.96 depressive events corrected for the times they had been assessed. The time during which BD patients were observed was not significantly different between the rs486055 genotypes. We found evidence that MMP-10 may be a mediator of the number of depressive phases during BD. Due to the limits of the study including the small-to-medium sample size, the naturalistic design and the possible occurrence of false-positive findings, independent analyses are warranted.

Original languageEnglish
Pages (from-to)76-82
Number of pages7
JournalNeuropsychobiology
Volume69
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Metalloproteases
Bipolar Disorder
Matrix Metalloproteinase 10
Matrix Metalloproteinase 17
Single Nucleotide Polymorphism
Homozygote
Matrix Metalloproteinases
Sample Size
Suicide
Antidepressive Agents
Therapeutics
Genotype
Pharmacology

Keywords

  • Bipolar disorder
  • Gene
  • Metalloproteinases
  • Single-nucleotide polymorphism

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Biological Psychiatry
  • Medicine(all)

Cite this

Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients. / Drago, Antonio; Monti, Barbara; De Ronchi, Diana; Serretti, Alessandro.

In: Neuropsychobiology, Vol. 69, No. 2, 2014, p. 76-82.

Research output: Contribution to journalArticle

Drago, Antonio ; Monti, Barbara ; De Ronchi, Diana ; Serretti, Alessandro. / Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients. In: Neuropsychobiology. 2014 ; Vol. 69, No. 2. pp. 76-82.
@article{82c4efdf21b447dd82e4a80d00952a96,
title = "Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients",
abstract = "Background: The genetic background of the antidepressant response to pharmacological treatment in bipolar disorder (BD) remains elusive. This issue is of primary relevance in that the depressive phases of BD are difficult to treat and they are associated with suicide. Aim: We investigated the role of a set of genetic variations (single-nucleotide polymorphisms) harbored by matrix metalloproteinases (MMPs) as predictors of response to treatment in depressed BD patients. Methods: 654 BD patients from the publicly available Systematic Treatment Enhancement Program for Bipolar Disorder study were investigated. The outcome was the number of depressive events corrected by the number of times patients were assessed. Clinical and sociodemographic variables were tested as possible stratification factors and included in the analysis if necessary. Genetic predictors were 43 SNPs harbored by 17 MMPs. Imputation, quality check and pruning were conducted according to standards. Results were corrected for multitesting. Results: rs486055 (MMP-10) was associated with the outcome. TT homozygotes had 5.08 ± 3.51 events, CT had 3.47 ± 3.18 and CC had 2.57 ± 2.96 depressive events corrected for the times they had been assessed. The time during which BD patients were observed was not significantly different between the rs486055 genotypes. We found evidence that MMP-10 may be a mediator of the number of depressive phases during BD. Due to the limits of the study including the small-to-medium sample size, the naturalistic design and the possible occurrence of false-positive findings, independent analyses are warranted.",
keywords = "Bipolar disorder, Gene, Metalloproteinases, Single-nucleotide polymorphism",
author = "Antonio Drago and Barbara Monti and {De Ronchi}, Diana and Alessandro Serretti",
year = "2014",
doi = "10.1159/000356971",
language = "English",
volume = "69",
pages = "76--82",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients

AU - Drago, Antonio

AU - Monti, Barbara

AU - De Ronchi, Diana

AU - Serretti, Alessandro

PY - 2014

Y1 - 2014

N2 - Background: The genetic background of the antidepressant response to pharmacological treatment in bipolar disorder (BD) remains elusive. This issue is of primary relevance in that the depressive phases of BD are difficult to treat and they are associated with suicide. Aim: We investigated the role of a set of genetic variations (single-nucleotide polymorphisms) harbored by matrix metalloproteinases (MMPs) as predictors of response to treatment in depressed BD patients. Methods: 654 BD patients from the publicly available Systematic Treatment Enhancement Program for Bipolar Disorder study were investigated. The outcome was the number of depressive events corrected by the number of times patients were assessed. Clinical and sociodemographic variables were tested as possible stratification factors and included in the analysis if necessary. Genetic predictors were 43 SNPs harbored by 17 MMPs. Imputation, quality check and pruning were conducted according to standards. Results were corrected for multitesting. Results: rs486055 (MMP-10) was associated with the outcome. TT homozygotes had 5.08 ± 3.51 events, CT had 3.47 ± 3.18 and CC had 2.57 ± 2.96 depressive events corrected for the times they had been assessed. The time during which BD patients were observed was not significantly different between the rs486055 genotypes. We found evidence that MMP-10 may be a mediator of the number of depressive phases during BD. Due to the limits of the study including the small-to-medium sample size, the naturalistic design and the possible occurrence of false-positive findings, independent analyses are warranted.

AB - Background: The genetic background of the antidepressant response to pharmacological treatment in bipolar disorder (BD) remains elusive. This issue is of primary relevance in that the depressive phases of BD are difficult to treat and they are associated with suicide. Aim: We investigated the role of a set of genetic variations (single-nucleotide polymorphisms) harbored by matrix metalloproteinases (MMPs) as predictors of response to treatment in depressed BD patients. Methods: 654 BD patients from the publicly available Systematic Treatment Enhancement Program for Bipolar Disorder study were investigated. The outcome was the number of depressive events corrected by the number of times patients were assessed. Clinical and sociodemographic variables were tested as possible stratification factors and included in the analysis if necessary. Genetic predictors were 43 SNPs harbored by 17 MMPs. Imputation, quality check and pruning were conducted according to standards. Results were corrected for multitesting. Results: rs486055 (MMP-10) was associated with the outcome. TT homozygotes had 5.08 ± 3.51 events, CT had 3.47 ± 3.18 and CC had 2.57 ± 2.96 depressive events corrected for the times they had been assessed. The time during which BD patients were observed was not significantly different between the rs486055 genotypes. We found evidence that MMP-10 may be a mediator of the number of depressive phases during BD. Due to the limits of the study including the small-to-medium sample size, the naturalistic design and the possible occurrence of false-positive findings, independent analyses are warranted.

KW - Bipolar disorder

KW - Gene

KW - Metalloproteinases

KW - Single-nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84895602104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895602104&partnerID=8YFLogxK

U2 - 10.1159/000356971

DO - 10.1159/000356971

M3 - Article

VL - 69

SP - 76

EP - 82

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 2

ER -